- Home
- KROS vs RGR Comparison
KROS vs RGR Comparison
Compare KROS & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- RGR
- Stock Information
- Founded
- KROS 2015
- RGR 1949
- Country
- KROS United States
- RGR United States
- Employees
- KROS N/A
- RGR N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- RGR Ordnance And Accessories
- Sector
- KROS Health Care
- RGR Industrials
- Exchange
- KROS Nasdaq
- RGR Nasdaq
- Market Cap
- KROS 589.8M
- RGR 610.8M
- IPO Year
- KROS 2020
- RGR N/A
- Fundamental
- Price
- KROS $11.84
- RGR $36.13
- Analyst Decision
- KROS Buy
- RGR
- Analyst Count
- KROS 11
- RGR 0
- Target Price
- KROS $45.33
- RGR N/A
- AVG Volume (30 Days)
- KROS 2.1M
- RGR 124.2K
- Earning Date
- KROS 02-26-2025
- RGR 02-19-2025
- Dividend Yield
- KROS N/A
- RGR 1.92%
- EPS Growth
- KROS N/A
- RGR N/A
- EPS
- KROS N/A
- RGR 1.73
- Revenue
- KROS $651,000.00
- RGR $520,485,000.00
- Revenue This Year
- KROS $303.27
- RGR N/A
- Revenue Next Year
- KROS N/A
- RGR $4.81
- P/E Ratio
- KROS N/A
- RGR $20.78
- Revenue Growth
- KROS 8037.50
- RGR N/A
- 52 Week Low
- KROS $9.78
- RGR $34.11
- 52 Week High
- KROS $73.00
- RGR $48.20
- Technical
- Relative Strength Index (RSI)
- KROS 24.87
- RGR 53.53
- Support Level
- KROS $10.95
- RGR $35.10
- Resistance Level
- KROS $11.63
- RGR $36.38
- Average True Range (ATR)
- KROS 0.87
- RGR 0.71
- MACD
- KROS 1.31
- RGR 0.23
- Stochastic Oscillator
- KROS 30.60
- RGR 88.99
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About RGR Sturm Ruger & Company Inc.
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The Company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.